Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 31, 2010

View Archived Issues

DermaPrep-delivered LC-002 shows promise in phase I/II trials in HIV

Preclinical and clinical data presented on BEZ-235

Efficacy and safety data from ECHO and THRIVE trials of rilpivirine reported

CADA blocks HIV entry by disrupting translocation of CD4 across ER membrane

HER2-Affitoxin is a potential therapeutic for HER2-overexpressing tumors

Repros Therapeutics submits analyzed data on Androxal to FDA

C3 Bio claims new inhibitors of proliferation of vascular smooth muscle cells

Merz Pharma patents novel NMDA receptor antagonists

Boehringer Ingelheim Pharma describes new 11-beta-HSD1 inhibitors

New antagonists of protease-activated PAR1 receptor presented

BioCancell Therapeutics completes preclinical studies of BC-821 for glioblastoma

Actavis launches risedronate in four European countries

Pfizer to purchase Akorn-Strides joint venture product portfolio

Transgenomic closes acquisition of Clinical Data's diagnostic business

Swedish Orphan Biovitrum returns rights to rozrolimupab to Symphogen

FDA approves Fortesta for hypogonadism

Meta-analysis data reported on pridopidine in Huntington's disease

Medimmune begins phase Ib/II trial of MEDI-575 in NSCLC

Compugen enters into funding agreement with Baize Investments

Immatics Biotech begins phase III IMA-901 trial in renal cell carcinoma

Axis-Shield provides update on Afinion albumin/creatinine ratio test

FG-3019 moves into phase II testing for idiopathic pulmonary fibrosis

Recordati and Merck Serono to comarket pitavastatin calcium in France

Concert Pharmaceuticals presents new deuterated NS3/NS4A protease inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...